Impact Biomedical drives mission-oriented discovery and development to pursue new products and treatment options in specialty biopharmaceuticals and consumer healthcare.
Our biopharmaceutical technologies have potential to advance treatment in oncology, neurology, and immunology. Consumer efforts include naturally based sugar alternatives, fragrances and insect repellents, as well antibacterial, antiviral, and antimicrobial technologies. A true spirit and desire of continuous improvement in healthcare result in continuous discovery of new technologies.
3F™ (Functional Fragrance Formulation) is a unique formulation of specialized ingredients (e.g. terpenes) from botanical sources with demonstrated effect as an insect repellent and an antimicrobial..
Equivir/Nemovir technology is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols that have proven antiviral effects with additional potential applications such as medication or supplements. .
LineBacker is a platform of small molecule X-bonded polyphenols. X-bonding is a molecular tuning technique that modifies a natural compound to induce potency, efficacy, bioavailability, without compromising safety standards..
Laetose™ technology is derived from a unique combination of sugar and inositol, which demonstrates the ability to inhibit the inflammatory and metabolic response of sugar alone, making it an ideal alternative..
Chairman of the Board
Chairman of the Board
An accomplished global business veteran of more than 40 years Mr. Chan Heng Fai specializes in financial restructuring and corporate transformation to unlock value and unleash entrepreneurial zeal while managing risk. He has successfully restructured more than 35 corporations in different industries and countries. Mr. CHan has served as a director of the Company since February 2017, and became Chairman of the Board of Directors in March 2019. He has also served as an officer of the Company’s wholly-owned subsidiary, DSS since July 2017. His expertise in banking and finance combined with his international business contracts qualify him to serve on our Board of Directors.
Frank D. Heuszel, 65, has served as a member of DSS’s Board of Directors since July 2018 during which time he served as chairman of the company’s Audit Committee until April 2019. On April 17, 2019, Mr. Heuszel was appointed by the DSS Board of Directors as the Chief Executive Officer of DSS (then known as Document Security Systems, Inc.) and its Interim Chief Financial Officer. In 2021, Mr. Heuszel assigned the Interim Chief Financial Officer to the current DSS CFO.
Heuszel has extensive expertise in a wide array of strategic, business, turnaround, and regulatory matters across several industries as a result of his executive management, educational, and operational experience. Prior to joining DSS, Mr. Heuszel had a very successful career in commercial banking and business turnaround management. For over 35 years, Heuszel served in many senior executive roles with major US and international banking organizations. As a banker Mr. Heuszel has served as General Counsel, Director of Special Assets, Credit Officer, Chief Financial Officer and Auditor. Mr. Heuszel has also operated a successful law practice which was focused on the regulation and operation of banks, management of bank litigation, corporate restructures, and merger and acquisitions. In addition to being an attorney and executive manager, Mr. Heuszel is a Certified Public Accountant (retired), and a Certified Internal Auditor. Mr. Heuszel is also a member of the Texas State Bar, the Houston Bar Association, Association of Corporate Counsel, Texas Society of Certified Public Accountants, and the State Bar of Texas Bankruptcy Section.
Dr. Brownell has diversified experience in the biopharmaceutical arena where she has played key roles in discovery, development, opportunity assessment, and Executive Leadership to drive
innovation. She has deep experience in discovery research and development through her history at Bayer Healthcare and venturebacked startups, with a focus on rare/orphan diseases, and the bench-to-clinic transition. She earned her BS in Biology from Allegheny College and MS, MPhil and PhD in Biology from Yale University.
Melissa Sims is a current member of the Board of Directors at Impact Biomedical. Sims has also enjoyed an illustrious legal career of more than two decades spanning a practice that includes real estate, municipal, mass tort, probate, and commercial litigation with Sanders Phillips Grossman, LLC, Wimbiscus Law Firm. In private practice, Sims argued a precedent-setting probate case before the Illinois Supreme Court. Recently, her groundbreaking local government preemption case was quoted as national precedent by the United States Supreme Court. Sims earned her bachelor’s degree from Illinois State University, attended Lewis University, and obtained her juris doctorate from Northern Illinois University, College of Law.